Lilly's Olumiant Makes Big Leap In Lupus Trial
Executive Summary
A couple of weeks after the setback of getting a worse-than-expected label from the FDA for Olumiant in rheumatoid arthritis (RA), Lilly has some strong Phase II data banked for its JAK inhibitor in lupus.